Dr. Seng H. Cheng

Seng H. Cheng, PhD, is Senior Vice President and Chief Scientific Officer of the Rare Disease Research Unit at Pfizer. Dr. Cheng obtained his BSc and PhD in Biochemistry at the University of London and trained as a postdoctoral fellow at the National Institute of Medical Research, U.K., in the field of tumor biology. He was Group Vice President of Genetic Diseases Science at Genzyme for 25 years researching solutions for patients with rare diseases. Prior to Joining Pfizer, he was the Global Head of Research of Rare Diseases at Sanofi where he led the pursuit of transformational therapies for patients with rare metabolic, neurological, neuromuscular, renal, pulmonary and hematological diseases. Dr. Cheng is experienced in bringing research programs from discovery through to early clinical development. He has co-authored 278 research articles and reviews and is a named co-inventor on 60 issued US patents in the area of biotechnology. As Chief Scientific Officer at Pfizer, he is charged with building upon the foundation of rare disease programs that are resident in the Rare Disease Category, with emphasis on gene therapy as an emerging therapeutic paradigm.